|
2026
|
Invention
|
Method of reducing bispecific t cell engager or chimeric antigen receptor t cell mediated cytokin... |
|
2025
|
Invention
|
Il-10 variant molecules and methods for treating inflammatory disease and oncology.
The applicat... |
|
|
Invention
|
Dual cytokine fusion proteins comprising multi-subunit cytokines.
The application relates to a d... |
|
2024
|
Invention
|
Dual cytokine fusion proteins comprising il-10.
The application relates to a dual cytokine fusio... |
|
2023
|
Invention
|
Dual cytokine fusion proteins comprising il-10. The application relates to a dual cytokine fusion... |
|
2022
|
Invention
|
Use of dual cytokine fusion proteins comprising il-10 and adoptive cell therapies or bispecific t... |
|
|
Invention
|
Dual cytokine fusions comprising il-10 and adoptive cell therapies or bispecific t-cell engagers ... |
|
|
Invention
|
Dual cytokine fusion proteins comprising multi-subunit cytokines. The application relates to a du... |
|
2021
|
Invention
|
Method of using genetic markers, snps and/or indels to determine responsiveness to il-10 treatmen... |
|
|
Invention
|
Method of using genetic markers, single nucleotide polymorphisms and/or indels to determine respo... |
|
2020
|
Invention
|
Il-10 variant molecules conjugated with antibody variable domain regions. The application relates... |
|
|
Invention
|
Il-10 variant molecules and methods of treating inflammatory disease. The application relates to ... |
|
|
Invention
|
Antibody-il-10 fusion proteins. The application relates to compositions or formulations comprisin... |
|
|
Invention
|
Methods for treating malignant tumors with il-10 variant conjugates. The application relates to c... |
|
|
Invention
|
Antibody variable domain regions fused to il-10 variant molecules. The application relates to com... |
|
|
Invention
|
Il-10 variant molecules and methods of treating inflammatory disease and oncology. The applicatio... |
